Free Newsletter
HIV/AIDS vax 'leapfrogs' immune system
A team of scientists says that inserting a gene into muscle successfully spurred production of antibodies that fought off HIV/AIDS in both mice and monkeys, offering an intriguing new approach to developing a vaccine for one of the world's deadlist killers.
"We used a leapfrog strategy, bypassing the natural immune system response that was the target of all previous HIV and SIV vaccine candidates," Dr. Philip R. Johnson of the Children's Hospital of Philadelphia told reporters. "Some years ago I came to the conclusion that HIV was different from other viruses for which we were trying to develop vaccines and we and might not ever be able to use traditional approaches."
Johnson's technique involved using a harmless adeno-associated virus to deliver an engineered DNA into the muscles of monkeys, spurring the protein production. Of nine monkeys tested, six never developed HIV and the others never developed AIDS. Developing a vaccine for use against HIV/AIDS has so far proven fruitless, despite decades of work.
- read the report from RedOrbit
Related Articles:
World AIDS day marked by new vaccine progress
HIV research summit seeks new discovery path
Woman's immune system may be key to HIV vax
Comments
TRADITIONAL APPROACH WILL BE THE BEST IN COMBATING HTE THREAT OF HIV/AIDS
Look up the defenition of insanity. Maybe the same thing isn't working
Um...they tried the traditional approach Christian Jusu...people are still dying from the disease...
I think this is amazing news!
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: